ArticleiScience2026
Generation of a distal lung cancer organoid model using oncogenic ret-expressing induced pluripotent stem cells.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tyrosine kinase receptor RET is altered by genetic fusions in a subset of non-small cell lung cancers (NSCLCs). To determine if we can generate organoids with lung cancer features in this context, we used two iPSC lines overexpressing oncogenic RET-M918T and RET-C634Y mutations. Lung progenitor cells (LPCs) were generated after 18 days of culture, followed by air-liquid interface cultures giving rise to alveolar structures expressing SFTPC, TTF-1, MUC1, and CK5/6 at day +38. Transplantation of LPCs into NOD/SCID mice generated tumors harboring bronchial structures, ciliated cells, goblet cells, and the squamous cell carcinoma marker p40. Single-cell RNA sequencing analyses allowed us to determine the major genes involved with response or resistance to Selpercatinib, a major inhibitor targeting RET-altered lung cancers. These findings show that the iPSC-derived preclinical model can recapitulate some features of NSCLC and has significant potential for identifying new therapeutic targets in RET-inhibitor-refractory lung cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.